IL2 and melanoma: In recent years, several combinations of anti-PD-1 and other therapies are being studied for melanoma, including combinations with interleukin-2 conjugates, oncolytic viral therapy, anti-lymphocyte activation gene (LAG)-3 antibodies, and IDO1 inhibitors [12].